2021
Case Report: Bullous Lung Disease Following COVID-19
Pednekar P, Amoah K, Homer R, Ryu C, Lutchmansingh DD. Case Report: Bullous Lung Disease Following COVID-19. Frontiers In Medicine 2021, 8: 770778. PMID: 34869488, PMCID: PMC8635639, DOI: 10.3389/fmed.2021.770778.Peer-Reviewed Case Reports and Technical NotesSARS-CoV-2 infectionBullous lung diseaseCoV-2 infectionRadiological abnormalitiesLung diseaseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus 2 infectionInterlobular septal thickeningPost-acute sequelaeGround-glass opacitiesFibrotic-like changesCoronavirus disease 2019COVID-19Mosaic attenuationSeptal thickeningSymptom onsetPulmonary diseaseRespiratory manifestationsParenchymal bandsCase reportDisease 2019InfectionDisease
2018
Chapter 13 Interstitial Lung Disease in the Connective Tissue Diseases
Antin-Ozerkis D, Rubinowitz A, Evans J, Homer R, Matthay R. Chapter 13 Interstitial Lung Disease in the Connective Tissue Diseases. 2018, 157-185. DOI: 10.1016/b978-0-323-48024-6.00013-6.Peer-Reviewed Original ResearchConnective tissue diseaseInterstitial lung diseaseCTD-ILDTissue diseaseLung diseaseIdiopathic interstitial lung diseaseFulminant respiratory failureRespiratory failureImmunosuppressive agentsHealthy patientsDrug reactionsFirst manifestationGradual onsetDiagnostic approachDiseaseCareful searchCommon formSubtle evidenceTreatmentDyspneaCorticosteroidsCoughPatientsInfectionDiagnosis
2016
Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease
Pillai PS, Molony RD, Martinod K, Dong H, Pang IK, Tal MC, Solis AG, Bielecki P, Mohanty S, Trentalange M, Homer RJ, Flavell RA, Wagner DD, Montgomery RR, Shaw AC, Staeheli P, Iwasaki A. Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease. Science 2016, 352: 463-466. PMID: 27102485, PMCID: PMC5465864, DOI: 10.1126/science.aaf3926.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAnimalsBacterial InfectionsCaspase 1CaspasesCaspases, InitiatorFemaleHumansImmunity, InnateInfluenza A virusInfluenza, HumanInterferon-betaMaleMembrane GlycoproteinsMiceMonocytesMyxovirus Resistance ProteinsNeutrophilsOrthomyxoviridae InfectionsRespiratory Tract InfectionsToll-Like Receptor 7Viral LoadYoung AdultConceptsBacterial burdenAntiviral resistanceNeutrophil-dependent tissue damageMyD88-dependent signalingAntiviral interferon productionCaspase-1/11IAV diseaseViral loadInfluenza diseaseOlder humansTissue damageInterferon productionInflammasome responseOlder adultsTLR7Vivo consequencesDiseaseMiceIAVBurdenMx geneHumansMonocytesMortalityInfluenza
2014
Pulmonary Fibrosis
Murray L, Homer R, Gulati M, Herzog E. Pulmonary Fibrosis. 2014, 2636-2653. DOI: 10.1016/b978-0-12-386456-7.05307-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInterstitial lung diseasePulmonary fibrosisLung fibrosisConnective tissue disease-related interstitial lung diseaseIdiopathic pulmonary fibrosisSalient clinical featuresDistinctive pathological featuresWound healing responseClinical featuresChronic injuryLung diseasePathological featuresCirculating BiomarkersInflammatory responseLung parenchymaCertain therapiesPathogenic mechanismsScar tissueClinical monitoringFibrosisHealing responseFatal natureGenetic formsDiseasePotential roleThoracic Neoplasia: Carcinoma
Politi K, Dela Cruz C, Homer R. Thoracic Neoplasia: Carcinoma. 2014, 2677-2689. DOI: 10.1016/b978-0-12-386456-7.05310-7.ChaptersLung cancerLung cancer subtypesDifferent natural historyLung cancer biologyCancer deathMolecular subtypesMouse modelNew therapiesSurvival rateCancer subtypesNatural historyLung cancer genomeTumor samplesDiseaseCell linesCancer biologyTherapyOngoing studiesCancerSubtypesRecent knowledgeMolecular mechanismsSpecific subsetPatientsCarcinoma
2012
Chronic inflammation and lung fibrosis: pleotropic syndromes but limited distinct phenotypes
Gifford AH, Matsuoka M, Ghoda LY, Homer RJ, Enelow RI. Chronic inflammation and lung fibrosis: pleotropic syndromes but limited distinct phenotypes. Mucosal Immunology 2012, 5: 480-484. PMID: 22806097, DOI: 10.1038/mi.2012.68.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisClinical entityHypersensitivity pneumonitisLung diseaseLung fibrosisDifferent clinical presentationsDistinct phenotypesPostinflammatory fibrosisClinical presentationRheumatoid arthritisChronic inflammationClinical syndromeTherapeutic responseClinical diseaseMultiple potential reasonsFibrosisFibrotic phenotypeExperimental modelDiseaseSyndromeMatrix depositionPhenotypePhenotypic distinctionPneumonitisInterstitial Lung Disease in the Connective Tissue Diseases
Antin-Ozerkis D, Rubinowitz A, Evans J, Homer RJ, Matthay RA. Interstitial Lung Disease in the Connective Tissue Diseases. Clinics In Chest Medicine 2012, 33: 123-149. PMID: 22365251, DOI: 10.1016/j.ccm.2012.01.004.Peer-Reviewed Original ResearchConceptsConnective tissue diseaseInterstitial lung diseaseLung diseaseTissue diseaseIdiopathic interstitial lung diseaseFulminant respiratory failureCTD-ILDRespiratory failureImmunosuppressive agentsHealthy patientsDrug reactionsFirst manifestationGradual onsetDiseaseCareful searchSubtle evidenceDyspneaCorticosteroidsCoughPatientsInfectionDiagnosis
2011
Modern concepts on the role of inflammation in pulmonary fibrosis.
Homer RJ, Elias JA, Lee CG, Herzog E. Modern concepts on the role of inflammation in pulmonary fibrosis. Archives Of Pathology & Laboratory Medicine 2011, 135: 780-8. PMID: 21631273, DOI: 10.5858/2010-0296-ra.1.BooksConceptsRole of inflammationIdiopathic pulmonary fibrosisPulmonary fibrosisTherapeutic interventionsResult of inflammationCell deathLung transplantationCytokine environmentMacrophage polarizationInflammationFibrosisLethal diseaseLimited biomarkersClinical contextDisease biomarkersBiomarkersDeathInterventionUnpublished researchTransplantationLungDisease
2010
Pulmonary Manifestations of Rheumatoid Arthritis
Antin-Ozerkis D, Evans J, Rubinowitz A, Homer RJ, Matthay RA. Pulmonary Manifestations of Rheumatoid Arthritis. Clinics In Chest Medicine 2010, 31: 451-478. PMID: 20692539, DOI: 10.1016/j.ccm.2010.04.003.Peer-Reviewed Original ResearchConceptsRheumatoid arthritisPulmonary diseaseLung diseaseInterstitial lung diseaseUse of drugsPulmonary manifestationsAirway diseaseRheumatoid nodulesPleural effusionRespiratory abnormalitiesPulmonary toxicityArthritisDiseaseDiagnostic assessmentMultidisciplinary approachMorbidityEffusionInfectionMortalityAbnormalities
2009
Granulomatous bronchiolitis of Crohn’s disease successfully treated with inhaled budesonide
Trow TK, Morris DG, Miller CR, Homer RJ. Granulomatous bronchiolitis of Crohn’s disease successfully treated with inhaled budesonide. Thorax 2009, 64: 546. PMID: 19478123, DOI: 10.1136/thx.2008.107185.Peer-Reviewed Original Research
2007
A Novel Pathway That Regulates Inflammatory Disease in the Respiratory Tract
Niu N, Le Goff MK, Li F, Rahman M, Homer RJ, Cohn L. A Novel Pathway That Regulates Inflammatory Disease in the Respiratory Tract. The Journal Of Immunology 2007, 178: 3846-3855. PMID: 17339484, DOI: 10.4049/jimmunol.178.6.3846.Peer-Reviewed Original ResearchConceptsAirway inflammationInflammatory diseasesRespiratory tractTh2-induced airway inflammationChronic airway inflammatory diseaseLymphocyte-deficient miceState of immunosuppressionAcute airway inflammationAirway inflammatory diseasesEffector Th cellsTh2 cells resultsAirway hyperresponsivenessInflammation wanesTh2 modelEffector Th1Respiratory illnessTh cellsInhalational exposureInflammationInhibitory effectSuch diseasesDiseaseStriking inhibitionTh1Localized treatmentTransforming Growth Factor (TGF)-β1 Stimulates Pulmonary Fibrosis and Inflammation via a Bax-dependent, Bid-activated Pathway That Involves Matrix Metalloproteinase-12*
Kang HR, Cho SJ, Lee CG, Homer RJ, Elias JA. Transforming Growth Factor (TGF)-β1 Stimulates Pulmonary Fibrosis and Inflammation via a Bax-dependent, Bid-activated Pathway That Involves Matrix Metalloproteinase-12*. Journal Of Biological Chemistry 2007, 282: 7723-7732. PMID: 17209037, DOI: 10.1074/jbc.m610764200.Peer-Reviewed Original ResearchConceptsMMP-12Pulmonary fibrosisWild typeGrowth factorInterstitial lung diseaseEffects of TGFMatrix metalloproteinase-12Pulmonary diseaseExaggerated productionPulmonary responseLung diseaseMMP-9Effector functionsTIMP-1Matrix metalloproteinaseFibrosisPotent stimulatorMetalloproteinase-12TGFBax activationInflammationPathogenesisBaxApoptosisDisease
2005
ERK1/2 mitogen-activated protein kinase selectively mediates IL-13–induced lung inflammation and remodeling in vivo
Lee PJ, Zhang X, Shan P, Ma B, Lee CG, Homer RJ, Zhu Z, Rincon M, Mossman BT, Elias JA. ERK1/2 mitogen-activated protein kinase selectively mediates IL-13–induced lung inflammation and remodeling in vivo. Journal Of Clinical Investigation 2005, 116: 163-173. PMID: 16374521, PMCID: PMC1319220, DOI: 10.1172/jci25711.Peer-Reviewed Original ResearchConceptsIL-13-induced inflammationIL-13IL-13 expressionSTAT6-independent mannerIL-13 stimulationLung inflammationSpecific chemokinesTg miceEffector responsesSystemic administrationMMP-2Alveolar remodelingInflammationLungCritical rolePotent activationTissue effectsERK1/2 activationSTAT6ChemokinesInhibitor PD98059ERK1/2ERK1/2 mitogenRemodelingDiseaseCase Study Review
Noble PW, Tanoue L, Homer R. Case Study Review. CHEST Journal 2005, 128: 540s-546s. PMID: 16304245, DOI: 10.1378/chest.128.5_suppl_1.540s.Peer-Reviewed Original Research
2003
Nonspecific Interstitial Pneumonia
Homer R. Nonspecific Interstitial Pneumonia. AJSP Review And Reports 2003, 8: 257-266. DOI: 10.1097/01.pcr.0000101943.54233.3e.Peer-Reviewed Original ResearchInterstitial lung diseaseNonspecific interstitial pneumoniaLung diseaseInterstitial pneumoniaDiffuse parenchymal lung diseaseConsensus classification systemIndividual patient prognosticationIdiopathic interstitial pneumoniaParenchymal lung diseaseTailoring of therapyPathologic featuresClinical featuresPatient prognosticationIndividual patientsPneumoniaDiseaseEuropean SocietyDistinct subgroupsSubgroupsWide spectrumClassification systemYearsPatientsTherapyClinicians
1998
ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES AS MARKERS FOR SYSTEMIC AUTOIMMUNE DISEASE
Homer R. ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES AS MARKERS FOR SYSTEMIC AUTOIMMUNE DISEASE. Clinics In Chest Medicine 1998, 19: 627-639. PMID: 9917957, DOI: 10.1016/s0272-5231(05)70107-6.Peer-Reviewed Original ResearchConceptsAntineutrophil cytoplasmic antibodyCytoplasmic antibodiesSpectrum of diseaseAntigen-specific assaysANCA testingSystemic vasculitisChest PhysiciansAutoimmune diseasesPretest probabilitySpecific antigenClinical useDiseaseSpecific testingSpecific assayAntibodiesAccurate assessmentVasculitisAntigenPhysiciansSignificant advances
1997
Eosinophilic pneumonia as a presentation of occult chronic granulomatous disease
Trawick D, Kotch A, Matthay R, Homer RJ. Eosinophilic pneumonia as a presentation of occult chronic granulomatous disease. European Respiratory Journal 1997, 10: 2166-2170. PMID: 9311521, DOI: 10.1183/09031936.97.10092166.Peer-Reviewed Original ResearchConceptsInvasive pulmonary aspergillosisChronic granulomatous diseaseAcute eosinophilic pneumoniaGranulomatous diseaseEosinophilic pneumoniaPulmonary aspergillosisSecond lung biopsyAcute lung diseaseHealthy young womenInvasive AspergillusLung histopathologyImmunocompetent patientsLung biopsyLung diseasePatientsPneumoniaYoung womenDiseaseAspergillosisPresentationImmunocompetentBiopsyGranulomasHistopathologySteroids